MERCK

 European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults whose tumors have no EGFR or ALK positive mutations.  


KEYTRUDA, the company’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy

Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

selumetinib, a MEK 1/2 inhibitor

KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

KEYTRUDA®

Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA® (lenvatinib) in Combination with KEYTRUDA® (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma 

LENVIMA®

KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20) 

KEYTRUDA®

Merck's doravirine shows treatment effect in late-stage HIV study

non-nucleoside reverse transcriptase inhibitor doravirine

Lilly

Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint 

Tradjenta® CARMELINA®

First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes

Humulin® R U-500

 Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease 

Trulicity® (dulaglutide)

 Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache 

Galcanezumab is a monoclonal antibody

 Lilly's Olumiant successful in mid-stage lupus study 

Olumiant® (baricitinib)

 Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors 

Jardiance®

Pfizer

 U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

XTANDI® (enzalutamide)

PFIZER AND LILLY ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 TRIAL OF TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS (OA) PAIN

Tanezumab is the first NGF inhibitor to receive Fast Track designation

 XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis 

XELJANZ® (tofacitinib citrate)

 Pfizer's Lyrica successful in late-stage pediatric epilepsy study 

LYRICA® (PREGABALIN)

 Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications 

XALKORI® (crizotinib)

 Pfizer's Tafamidis a Breakthrough Therapy for rare heart disorder 

Tafamidis

Bristol-Myers Squibb

 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma 

Empliciti® (elotuzumab)

 European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection 

Opdivo® (nivolumab)

 Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan 

Yervoy® (ipilimumab)

 U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden ≥10 mut/Mb 

Opdivo® Plus Low-Dose Yervoy®

 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma 

Opdivo®

 China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) 

Opdivo® (nivolumab injection)

Amgen

 Expanded label for Amgen's Repatha approved in Europe

Repatha®

 FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention 

Aimovig™ (erenumab-aooe)

 European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis 

Prolia® (denosumab)

 Amgen Crushes Second-Quarter Revenue, Profit Expectations

Amgen Reports Second Quarter 2018 Financial Results

 Neulasta is used to reduce the risk of infection during chemotherapy treatment. 

Neulasta®, (Pegfilgrastim)

 FDA Panel Recommends Enbrel for Pediatric Patients

ENBREL® (etanercept)

AstraZeneca

 Lokelma approved in the US for the treatment of adults with hyperkalaemia 

Lokelma (sodium zirconium cyclosilicate), formerly ZS-9

Tezepelumab granted Breakthrough Therapy designation for the treatment of patients with severe asthma without an eosinophilic phenotype

Tezepelumab is a first-in-class anti-TSLP monoclonal antibody

 Regulatory submission in Japan for Forxiga in type-1 diabetes 

Forxiga®(dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor

 IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer 

IMFINZI® (Durvalumab)

 Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer 

Lynparza™(olaparib) tablets

 Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes 

Bydureon® (2mg prolonged-release suspension for injection)

Gilead

 European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy 

Yescarta® (axicabtagene ciloleucel)

China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection

Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide)

 European Commission Grants Marketing Authorization for Gilead’s Biktarvy®(Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection 

Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

 Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline 

Collaboration With National Cancer Institute

 

Gilead, Galapagos hit goal in psoriatic arthritis phase 2 -

​Gilead and Galapagos disclosed the data alongside news that filgotinib has cleared a phase 2b futility analysis in ulcerative colitis. (Gilead China)

filgotinib

 Gilead Sciences: Still My Top Biotech Pick For The Next Decade

the company is sitting billions of dollars.

Celgene

 Celgene Announces Phase III ‘AUGMENT’ Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint 

REVLIMID® in Combination with Rituximab (R²)

 Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

ABRAXANE®

 Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes 

Luspatercept

 Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO 

lisocabtagene maraleucel (liso-cel; JCAR017), an investigational CD19-directed CAR T cell therapy

 Bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

 Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program

Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program

abbvie

 AbbVie's elagolix shows positive effect in late-stage extension study in uterine fibroids

ORILISSA™ (elagolix)

 IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab)

 AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy 

How does VENCLEXTA® + rituximab work?

 AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program 

Ibrutinib (IMBRUVICA®)

AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan

HUMIRA®

 AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

venetoclax in combination with an HMA (azacitidine or decitabine), and M14-387, a Phase 1/2 trial of venetoclax in combination with LDAC.

Johnson & Johnson

 Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen 

DARZALEX® (daratumumab)

New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation 

XARELTO® (rivaroxaban)

 Johnson & Johnson enlists diabetes veteran Merck KGaA to market Invokana in China 

Invokana™

 China's innovation and competence growing: J&J chairman 

Johnson & Johnson Opens a New Asia Pacific Headquarters

 Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression

esketamine nasal spray

 Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer 

Erdafitinib, an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor

BeiGene

 BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China

Tislelizumab (BGB-A317)

 BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM) 

BTK Inhibitor Zanubrutinib

 BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma 

Tislelizumab (BGB-A317), a PD-1 inhibitor,

 BeiGene's NDA for anti-pd-1 antibody tislelizumab in hodgkin’s lymphoma accepted in China

tislelizumab, an investigational anti-PD-1 antibody

 BeiGene's first NDA for zanubrutinib approved in China for the treatment of relapsed/refractory MCL

zanubrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor,

 BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China 

REVLIMID® (lenalidomide) is currently marketed in China by BeiGene under an exclusive license from Celgene Corporation.

Novartis

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

KISQALI® (ribociclib)

 FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

GILENYA™ is a sphingosine 1-phosphate receptor modulator

 FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

PROMACTA® is a thrombopoietin receptor

 Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

Kymriah® (tisagenlecleucel)

Gilenya® (fingolimod)

Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe

 Basel, November 29, 2018  

Novartis today announced that the European Commission (EC) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to 17 years old with relapsing-remitting forms of multiple sclerosis (RRMS).

 European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma

TAFINLAR®, in combination with MEKINIST®

Biogen

 Biogen and Eisai's BAN2401 shows positive effect in mid-stage Alzheimer's study

BAN2401 (Aβ mAb) Alzheimer’s disease

 SAMSUNG BIOEPIS AND BIOGEN ANNOUNCE POOLED ANALYSIS RESULTS OF ANTI-TNF BIOSIMILARS BENEPALI™ (ETANERCEPT), FLIXABI™ (INFLIXIMAB), AND IMRALDI™ (ADALIMUMAB) AT EULAR 2018 

three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI™ (SB4, etanercept biosimilar), FLIXABI™ (SB2, infliximab biosimilar), and IMRALDI™ (SB5, adalimumab biosimilar)

 Enrollment underway in late-stage study of Biogen's BIIB093 in severe type of ischemic stroke

Biogen's BIIB093

 In a partnership with Japanese pharmaceutical company Eisai Co. Ltd. (TSE:4523), the Cambridge, Massachusetts-based biotech company treated 856 patients who had early-stage Alzheimer’s disease with varying dosages of BAN2401. 

BAN2401 is an anti-amyloid beta protofibril antibody

 NEW SPINRAZA® (NUSINERSEN) DATA UNVEILED AT AAN ANNUAL MEETING SHOW CONTINUED IMPROVEMENT IN MOTOR FUNCTION FOR BROAD AGE RANGE AND SURVIVAL BENEFIT FOR INFANTS 

SPINRAZA®

  BIOGEN REPORTS QUARTERLY REVENUES OF $3.1 BILLION 

Total revenues of $3.1 billion, an 11% increase versus the prior year or a 15% increase 

BIIB Stock Quote & Chart

Roche

 FDA Grants Breakthrough Therapy Designation for Genentech’s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Avastin® (bevacizumab) is a tumor-starving (anti-angiogenic) therapy

 Roche reveals that TECENTRIQ in combination with Celgene's Abraxane improves progression-free survival in patients with front-line metastatic triple-negative breast cancer. 

TECENTRIQ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel])

 Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy 

TECENTRIQ®

 Roche's antiviral balovavir marboxil successful in late-stage study

Baloxavir marboxil – an investigational oral, single-dose antiviral

 Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Venclexta® (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC

 New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia 

GAZYVA® (obinutuzumab) is a prescription medicine used in combination with chemotherapy

Vertex

 Sep 6, 2018

Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis

SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor)

  Sep 3, 2018 

Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation

ORKAMBI® (lumacaftor/ivacaftor)

  Aug 7, 2018 

FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease 

ORKAMBI® (lumacaftor/ivacaftor)

 Aug 15, 2018 

 FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene

KALYDECO® (ivacaftor)

 Jun. 28, 2018

- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada approved PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene 

PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor)

  Jun 18, 2018 

Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

ORKAMBI® (lumacaftor/ivacaftor

Regeneron

 August 17, 2018 

FDA APPROVES EYLEA® (AFLIBERCEPT) INJECTION SBLA IN WET AGE-RELATED MACULAR DEGENERATION 

EYLEA® (AFLIBERCEPT)

 

TARRYTOWN, N.Y. and PARIS, Sept. 28, 2018 /PRNewswire/ -- 

Libtayo is the third anti-PD-1 approved in the U.S.

CSCC is the second most common skin cancer in the U.S.

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Libtayo®  

FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma 

September 28, 2018 at 4:39 PM EDT Back FDA APPROVES LIBTAYO® (CEMIPLIMAB-RWLC) AS FIRST AND ONLY TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA TARRYTOWN, N.Y. and PARIS, Sept. 28, 2018 /PRNewswire/ --

 June 4, 2018 

NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PIVOTAL CEMIPLIMAB TRIALS SHOWING POSITIVE RESULTS IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

CEMIPLIMAB

 May 21, 2018 

NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES TWO POSITIVE PHASE 3 TRIALS SHOWING DUPIXENT® (DUPILUMAB) IMPROVED MODERATE-TO-SEVERE ASTHMA

DUPIXENT® (DUPILUMAB)

  May 16, 2018   

POSITIVE PHASE 3 TRIAL OF DUPIXENT® (DUPILUMAB) IN ADOLESCENTS WITH INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS 

DUPIXENT® (DUPILUMAB)

  March 10, 2018  

PRALUENT® (ALIROCUMAB) INJECTION SIGNIFICANTLY REDUCED RISK OF CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS, AND WAS ASSOCIATED WITH LOWER DEATH RATE 

PRALUENT® (ALIROCUMAB) INJECTION

Biomarin

 BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia 

Vosoritide

 BioMarin Receives Milestone Payments from Pfizer for Talazoparib 

Talazoparib

 BioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease 

Palynziq™ (pegvaliase-pqpz) Injection

 BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress 

valoctocogene roxaparvovec

 BioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018 

tralesinidase alfa

 BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies 

Valoctocogene roxaparvovec is gene therapy designed for the treatment of Hemophilia A.

Allergan

 DUBLIN, Oct. 17, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN)   

Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

 DUBLIN, Sept. 26, 2018 /PRNewswire/ -

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for VRAYLAR® (cariprazine), seeking to expand the indication to include the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults in the current product label. 

VRAYLAR is a once-a-day medication, taken with or without food, for the acute treatment of manic or mixed episodes of bipolar I disorder in adults. In clinical studies, VRAYLAR was proven to help manage manic and mixed episodes of bipolar I disorder.

 Allergan Presents New Research at the American College of Gastroenterology Annual Scientific Meeting (ACG 2018)

Mon October 8, 2018 8:00 AM|PR Newswire|About: AGN 

VIBERZI is a prescription medicine that helps you proactively manage IBS-D abdominal pain and diarrhea

 Allergan to file U.S. marketing application for migraine med ubrogepant by next quarter

Oct. 17, 2018 8:22 AM ET|About: Allergan plc (AGN)|By: , SA News Editor  

Advancing the Pipeline Key programs in development that derive from our Open Science pipeline

Seattle Genetics

EA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma-

 Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple MyelomaNovember 14, 2018 at 8:00 AM EST

-SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma-

-Adds to Seattle Genetics’ Robust Clinical-Stage Development Pipeline across Multiple Hematologic and Solid Tumors-

BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 14, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN)

We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN)

 Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 CongressOctober 8, 2018 at 6:50 PM EDT

  • Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 8, 2018-- Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) 

Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer October 08, 2018 06:50 PM Eastern Daylight Time COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN)